topics nippon 
LexBlog IP
FEBRUARY 10, 2022
Earlier this week, the Federal Circuit was given another opportunity to explore this topic, and the potential policy consequences of such private agreements. In Nippon Shinyaku Co. Sarepta Therapeutics, Inc., Sarepta Therapeutics, Inc.,
Fish & Richardson Trademark & Copyright Thoughts
FEBRUARY 7, 2022
and Nippon Shinyaku Co., Denials of institution – particularly the extent to which they are reviewable – have long been a contentious topic for the PTAB. The most active petitioners in 2021 were Sarepta Therapeutics, Inc., Spectrum Solutions LLC, JSR Corporation, and Fresenius Kabi USA LLC. Regeneron Pharmaceuticals, Inc.,
Expert insights. Personalized for you.
52 
Let's personalize your content